A correlation between BCL-2 modifying factor, p53 and livin gene expressions in cancer colon patients

Eman AE. Badr\textsuperscript{a,∗}, Mohamed FA. Assarb, Abdel Monem A. Eltorgomanc, Azza Zaghlol Labeebd, Gehad A. Breakac, Enas A. Elkhoulye

\textsuperscript{a} Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine – Menoufia University, Egypt
\textsuperscript{b} Biochemistry Division of Chemistry Department, Faculty of Science – Menoufia University, Egypt
\textsuperscript{c} Department of Organic Chemistry, Faculty of Science – Menoufia University, Egypt
\textsuperscript{d} Department of Medical Microbiology and Immunology, Faculty of Medicine – Menoufia University, Egypt
\textsuperscript{e} Clinical Oncology Department, Faculty of Medicine, Menoufia University, Egypt

\textbf{ARTICLE INFO}

\textbf{ABSTRACT}

Accumulating evidence has revealed that livin gene and BCL-2 modifying factor (BMF) gene are closely associated with the initiation and progression of colon carcinoma by activating or suppressing multiple malignant processes. Those genes that can detect colon - cancer are a promising approach for cancer screening and diagnosis. This study aimed to evaluate correlation between livin, BMF and p53 genes expression in colon cancer tissues of patients included in the study, and their relationship with clinicopathological features and survival outcome in those patients. In this study, 50 pathologically diagnosed early cancer colon patients included and their tissue biopsy with 50 matched adjacent normal tissue, and 50 adenoma tissue specimens were analyzed for livin gene and BMF gene expressions using real time PCR. The relationship of those genes expressions with clinicopathological features, tumor markers, Time to Progression and overall survival for those patients were correlated in cancer colon group. In this study, there was a significant reciprocal relationship between over expression of livin gene and down regulation of BMF and p53 genes in colon cancer cells. Livin mRNA was significantly higher, while BMF and p53 mRNA were significantly lower in colorectal cancer tissue compared to benign and normal colon tissue specimens (P < 0.001), however, this finding was absent between colon adenomas and normal mucosa. There was a significant association between up regulation of livin and down regulation of BMF and p53 expressions with more aggressive tumor (advanced TNM stage), rapid progression with metastasis and decreased overall survival in cancer colon patients, hence these genes can serve as significant prognostic markers of poor outcome in colon cancer patients. This work highlights the role of livin, BMF and p53 genes in colorectal tumorigenesis and the applicability of using those genes as a diagnostic and prognostic markers in patients with colon carcinoma and as a good target for cancer colon treatment in the future.

\textbf{1. Introduction}

Human cancer colon is a common malignancy worldwide. It is the second most common diagnosed cancer in females and the third in males, with almost 835,000 deaths in 2015 [1]. In Egypt, There is high incidence of cancer colon among the young Egyptian population under 40 years. So, awareness must be present about the potential for cancer colon [2].

A subset of hyperplastic polyps, especially micro-vesicular hyperplastic polyps, progress to serrated neoplasms (SSP or TSA) and a fraction of these serrated neoplasms progress to Cancer colon. There are a large number of factors that play a direct role in driving the polyp → cancer colon sequence, including gene mutations, epigenetic alterations, and local inflammatory changes [3].

Alterations in key pathways that directly or indirectly regulate apoptosis may affect tumor cell survival. So, apoptosis regulators play a role in colon cancer treatment and prevention, by selective induction of apoptosis in cancer cells [4].

Livin is novel member of the inhibitor of apoptosis protein family, that is considered a new anti-apoptotic oncogene due to its unique structure, ability to protect cells against a series of specific allergen-induced stimulation and inhibition of apoptosis [5]. It is a new biomarker that is able to accurately and reliably detect cancer colon at its earliest stages representing a promising alternative approach for its
The protein encoded by proapoptotic BCL-2 modifying factor (BMF) gene belongs to the BCL2 (B-cell lymphoma 2) family. This BCL-2 family proteins regulate activation of the intrinsic apoptotic pathway. BCL-2 family includes anti-apoptotic members (Bcl-2L, Bcl-extra-large and Mcl1) and other pro-apoptotic. The pro-apoptotic BCL-2 family members can be further divided into the multi-BH-domain (containing BH1, BH2 and BH3 domains) and the BH3-only proteins (only region of homology to BCL-2 is BH3). Among BH3-only proteins extensively studied up till now, PUMA, NOXA and BIM (Bcl-2 interacting mediator of cell death) whereas little is known about their closest relative, BMF [7].

In this study we attempt to evaluate livin and BMF genes expression in colon cancer tissues for patients included in the study, and investigate the correlation between them, and with clinicopathological features and survival outcome in those patients.

2. Patients and methods

This study was carried out on 50 pathologically proven cancer colon patients between June 2017 and August 2019; diagnosed at Surgery Departments while treated & followed up at Clinical Oncology Department, Menoufia University. In addition 50 patients with colorectal adenoma were included in the study. An informed written consent was obtained from all participants. The protocol was approved by the Ethical Committee of Medical Research, Faculty of Medicine, Menoufia University.

All participants were subjected to full history taking, clinical examination, complete laboratory investigations included: liver and kidney function tests, determination of serum carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) were determined. Adequate imaging of the chest and abdomen should be obtained for staging purposes, ideally preoperatively. Abdominal/pelvic computed tomography (CT), and abdominal/pelvic magnetic resonance imaging (MRI) scans are appropriate for imaging the abdomen and liver, for the purpose of staging. Imaging studies may also include a chest radiograph or chest CT scan, an abdominal barium study to better delineate the primary lesion preoperatively, and bone scan. Positron emission tomography (PET) scanning is emerging as a very useful modality for staging and assessment of colorectal cancers. The newest addition, a fusion PET-CT scan, allows for detection of metastatic deposits and has the added tissue-based resolution of CT.

Cancer colon patients were staged based on clinical TNM classification and early & advanced stage were included. The pathological grading was based on the world health organization (WHO) criteria, and performance status was estimated based on ECOG classification [8]. Demographic data of the patients, Body mass index (BMI), tumor characteristics (site, side, regional node status, histological characteristics, and grade) were reported.

All patients with stage III and high-risk stage II colon cancer received adjuvant FOLFOX chemotherapy regimen which is given over 2 days. The regimen is repeated for 12 cycles, every 2 weeks. All cases of metastatic disease, FOLFOX regimen was the first line regimen and evaluated by CTs and tumor markers (CEA & CA 19.9) every 2–3 months. Patients finished chemotherapy were followed by CTs and tumor markers every 3 months and colonoscopy on annual bases. Response assessment was done based on RECIST criteria. Follow-up was completed for all patients until August 2019.

The study used 150 tissue specimens collected from 100 patients, underwent surgery or colonoscopic biopsy; for Livin and BMF gene expressions estimation. They were categorized according to histopathological diagnosis as follows: Group I: 50 tissue specimens for patients with colon adenocarcinoma, Group II: 50 tissue specimens for patients with colon adenoma, and Group III: 50 tissue specimens of accompanying normal colon mucosa from same patients in group I for comparison.

Tissue samples from the cancerous tissue, adjacent healthy marginal and colon polyp were taken. The tissue was homogenized in trizol reagent using a Qiagen Tissuelyzer, with a stainless steel bead added to the sample to beat the tissue into solution. Total RNA was extracted from tissue by Direct-zol™ RNA MiniPrep kit, Zymo Research.

Two-step RT-PCR was done, for reverse transcription step, samples were prepared in a final volume of 20 μl containing RT buffer, Multi scribe reverse transcriptase (PE Applied Biosystems), and 20 ng total...
RNA. Then the samples were incubated at 25 °C for 10 min and at 48 °C for 30 min. Heating to 95 °C for 5 min inactivated the reverse transcriptase on 2720 thermal cycler Singapore.

For cDNA amplification the sequence of primers of livin Forward primer TGAGGAGTTGCGTCTGG Reverse primer GCACGGCACAAAGA CGAT, BMF Forward primer CCGTTGGGAGGAGCCCCTG Reverse primer GCCATGGAACTGGTCTGCAA, primers of PS3, Forward primer ATCTAGAGCCACCGTCCA Reverse primer TCTGACGACACCTATTG CAAGC and primers of GAPDH as endogenous control, forward primer GTCTCCTCTGACTTCAACAGCG, reverse primer ACCACCTGTTCGTG TAGCCAA were used with SensiFAST™ SYBR® Lo-ROX Kit, nuclease-free water, cDNA in a total reaction volume 25 μl and using GAPDH as endogenous control using the 7500 Real-time PCR system (Applied Biosystems, Foster City, CA, USA).

Using the comparative CT method, endogenous controls were used to normalize the target genes expression levels by correcting differences in the amount of cDNA loaded into PCR reactions. Fig. 1a and b shows the amplification plot and melting curve of livin gene expression. While Fig. 2 a and 2b show the amplification plot and melting curve of BMF gene expression.

Regarding statistical analysis, Qualitative data were described using number and percent and was compared using Chi-square test or Fisher Exact test, while normally quantitative data were expressed in mean ± SD and was compared using F test (ANOVA) abnormally distributed data was expressed in median (Min. - Max.) And was compared using Kruskal Wallis test. Normally quantitative data were expressed in mean ± SD and was compared using F test (ANOVA) abnormally distributed data was expressed in median (Min. – Max.) and was compared using Mann Whitney test for two groups and Kruskal Wallis test for more than two groups. P-value ≤ 0.05 was considered statistically significant.

3. Results

Fifty pathologically proven cancer colon patients diagnosed and treated between June 2017 and August 2019; were included in this study. The study used 150 tissue specimens collected from 100 patients, underwent surgery or colonoscopic biopsy; for Livin and BMF gene expressions estimation. They were categorized according to histopathological diagnosis as follows: Group I: 50 tissue specimens for patients with colon adenocarcinoma, Group II: 50 tissue specimens for patients with colon adenoma, and Group III: 50 tissue specimens of
accompanying normal colon mucosa from same patients in group I for comparison.

The demographic features of the patients are summarized in table (1), where no significant difference was detected between patients with colorectal cancer (group I) and patients with benign colorectal polyp (group II), indicating they were well matched (Table 1).

The expression of livin gene was significantly higher in colorectal cancer tissue compared to benign and paired normal colorectal specimens ($P < 0.001$), however, the colorectal cancer group showed statistically significant lower BMF and p53 genes expression compared to the others two groups ($P < 0.001$).

Comparing the levels of livin, BMF and p53 mRNA among colon adenomas and normal mucosa did not show a significant difference (Table 2). A remarkable reciprocal relation between up regulation of livin and down regulation of BMF and p53 genes expressions in colon cancer tissue was observed.

Spearman’s correlation analysis was conducted to display the impact of BMF gene expression on livin and p53 genes expression in colorectal specimens (cancer, benign and paired normal mucosa), and on cancer patients prognosis; in terms of overall survival (OS) and time to disease progression (TTP), (Table 3 and Fig. 3a,b,3c). There was a significant negative correlation between BMF, p53 genes and livin gene expressions, as lower BMF and p53 genes expression in cancer tissue was significantly associated with higher livin gene expression. But a positive correlation was detected with OS and TTP, only in cancer group.

Similarly, the impact of livin gene expression on the same parameters was summarized in Table (4) and fig (4a, 4b). There were significant inverse correlations between livin gene expression, BMF gene expression, TTP and OS in colorectal cancer patients; higher livin gene expression in cancer tissue was significantly associated with decreased BMF gene expression, ($P < 0.001$).

Spearman’s correlation analysis confirmed the reciprocal relationship between livin and BMF gene expressions in colon cancer tissue. Remarkably, only increased livin and decreased BMF genes expressions were significantly associated with decreased overall CRC patients survival ($r = 0.550, P < 0.001$ with BMF gene, $r = -0.505, P < 0.001$ with livin gene) and rapid disease progression (shorter TTP).

The expressions of BMF, p53 and livin genes in colon cancer tissue was significantly related to clinical tumor stage (TNM) and presence of metastasis ($P < 0.001$), Most of colon cancer patients were stage IV disease (46%) followed by stage III (40%) then stage II (14%). Notably, patients with higher BMF gene, p53 and lower livin gene tissue expressions were significantly presented in stage II cancer (7/50) and without metastasis (27/50; 47%), However, patients with higher livin gene and lower BMF, p53 gene expressions were totally presented in stage IV disease with tumor metastasis (23/50; 46%), (Table 5).

4. Discussion

Cancer colon is one of the leading causes of cancer associated death globally. This may be due to little understanding of the colon cancer molecular controls conferred by apoptotic and anti-apoptotic genes [9].

Apoptosis is considered the main protection against tumor, as the ability of tumor cells to evade apoptosis is the mainstay during ontogenesis. A complex network of pro-apoptotic and anti-apoptotic genes can govern the regulation of apoptosis, and their balance can determine the cellular fate and ensure human health [7].

Livin, is a novel member of the inhibitors of apoptosis protein family (IAP), suppresses apoptosis through inhibition of caspases, protein degradation, and also can affect mitosis. Livin has been implicated in the development and progression of CRC [10].

Proapoptotic BCL-2 modifying factor (BMF) gene is a member of BH3-only proteins, but, its role in apoptosis signaling, and oncogenesis, still unclear. In many cell lines, BMF serves a role in initiating cell apoptosis by binding to B-cell lymphoma (Bcl)2, Bcl-XL and Bcl-w proteins, and showed pro-apoptotic potential in many cell lines and cell death assays [7,11].

In this work, livin gene and BMF gene mRNA expression levels in
different colorectal tissue specimens (50 cancer, 50 benign and 50 paired normal mucosa samples) were assessed.

The hallmark finding in this study, is the reciprocal correlation between the up regulation of livin gene and down regulation of BMF gene expressions in colon cancer tissues (r = -0.550, P < 0.001). Livin mRNA was significantly higher, while BMF mRNA was significantly lower in colorectal cancer group compared to benign and normal colorectal tissue specimens (P < 0.001), however, such relation was absent between colon adenomas and normal mucosa. This may indicate that, upregulation of livin gene in cancer tissues could suppress cell apoptosis in the phase of adenoma to adenocarcinoma sequence and possibly livin status had an influence on colorectal carcinogenesis by apoptosis inhibition [10]. Supportive evidence was added by Xi et al., as they suggested that livin had an oncogenic role in CRC and overexpression of this gene is a growth factor for development and proliferation of colon cancer cells [12]. Also, Myung et al. confirmed that livin expression in colon cancer tissues was up-regulated

Table 1
Demographic characteristics of the studied patients.

| Variables            | Cancer colon cases (n = 50) | Colon adenoma cases (n = 50) | Test of Sig. P |
|----------------------|-----------------------------|-----------------------------|----------------|
| Sex n (%)            |                             |                             |                |
| Male                 | 22 (44%)                    | 27 (54%)                    | χ² = 2.083 0.353|
| Female               | 28 (56%)                    | 23 (46%)                    |                |
| Age (years)          | Mean ± SD. 49.90 ± 11.10    | 50.06 ± 10.96               | F = 0.317 0.729|
| BMI (kg/m²)          | Mean ± SD. 26.04 ± 5.1       | 25.70 ± 3.65                | F = 0.610 0.544|

There was a non significant difference of sex, age and BMI in different studied groups.

Fig. 2b. the melting curve of BMF gene expression.
compared to that in paired normal mucosa at the mRNA and protein levels [13]. Notably, livin gene not only had a role in colorectal tumorigenesis, but also it blocks death receptors and chemotherapy-induced apoptosis during treatment [10].

The BCL-2 family proteins members comprise the sentinel network of apoptotic response. Knockdown of BMF gene and other members of the pro-apoptotic BH3-only proteins, facilitates tumor progression, and permits the survival of malignant clones [7].

Another pro-apoptotic factor is p53 protein that transactivates downstream targets that mediate apoptosis or cell cycle arrest. p53 is a transcriptional regulator that reduced AKT phosphorylation, induced BCL2-modifying factor (BMF) expression, sensitized BIM dissociation from BCL-XL and induced mitochondria-dependent apoptosis in cancer cells [14].

In this study, lower expression of BMF gene in colon cancer tissues compared to adenoma and normal tissues was detected. In accordance with this result, an array-based screen study on human colon cancer cells implicated BMF gene as a critical player and key regulator of apoptosis and tumor inhibition [15]. In a recent review, loss of BMF gene has been shown to accelerate tumor progressions in several tumors [11]. BMF gene serves a role of tumor suppressor gene, in a variety of tumor types including, lymphoma, colorectal cancer, and breast cancer, consequently, decreased its expression enhances tumorigenesis

Table 2
Livin, BMF and p53 genes expression levels among the three groups.

| Gene               | Cancer Colon specimens (n = 50) | Colon adenoma specimens (n = 50) | Normal mucosa specimens (n = 50) | P       | Post hoc test (Dunn’s) |
|--------------------|-------------------------------|---------------------------------|---------------------------------|---------|------------------------|
|                    | Median (min.max.)              | Median (min.max.)               | Median (min.max.)               |         | Cancer vs. benign      |
| BMF gene expression| 1.35 (0.45–5.8)                | 4.24 (3.09–29.92)               | 17.17 (7.12–29.9)               | < 0.001*| < 0.001*               |
| Livin gene expression| 17.16 (4.23–26.5)             | 1.15 (0.06–16.04)               | 1.14 (0.06–15.84)               | < 0.001*| < 0.001*               |
| PS3 gene expression| 1.56 (0.93–6.1)               | 10.15 (8.6–12.4)                | 11.1 (8.3–15.8)                 | < 0.001*| < 0.001*               |

P values for Kruskal Wallis test, sig. bet. groups was done using Post Hoc Test (Dunn’s test).

*Statistically significant at p ≤ 0.05.

There was a significant difference between the three groups regarding gene expression of livin, BMF and p53.

Table 3
BMF gene expression and clinical data in each group.

| BMF gene expression | Cancer colon cases (n = 50) | Colon adenoma cases (n = 50) | Normal mucosa specimens (n = 50) |
|--------------------|----------------------------|-------------------------------|---------------------------------|
| r_s                 | P                          | r_s                          | P                               |
| BMI (kg/m^2)        | −0.170                     | 0.238                         | 0.079                           | 0.586  | –                      |
| Age (years)         | −0.008                     | 0.953                         | 0.040                           | 0.784  | –                      |
| Performance state   | −0.082                     | 0.570                         | –                               | –      | –                      |
| Time to progress (TTP) | 0.633*                   | < 0.001*                     | –                               | –      | –                      |
| Overall survival    | 0.550*                     | < 0.001*                     | –                               | –      | –                      |
| Livin gene expression| −0.565*                    | < 0.001*                     | −0.112                          | 0.438  | < 0.009               |
| PS3 gene expression | 0.436                      | 0.035*                        | 0.212                           | 0.180  | 0.206                 |

r_s: Spearman coefficient *Statistically significant at p ≤ 0.05.

In cancer colon cases: There was a significant positive correlation between BMF gene expression and each of TTP, overall survival and p53 gene expression. While there was a significant negative correlation between BMF and livin gene expression.

Fig. 3a. A positive correlation between BMF gene expressions in cancer colon patients and Time to progress (TTP).

Fig. 3b. a positive correlation between BMF gene expression in cancer colon patients and Overall survival.

from BCL-XL and induced mitochondria-dependent apoptosis in cancer cells [14].
Additionally, in a recent clinical trial to investigate the role of histone deacetylase (HDAC) inhibitor as an anticancer agent that regulate BMF gene activity and trigger BMF-mediated apoptosis, this drug showed improved therapeutic approach for treating colon cancer and other conditions, also the same study proved that HDAC can bind with BMF gene in colon cancer cells, and establish a pro-survival scenario in colon cancer cells [17].

In this study, for the first time we identified a reciprocal relationship between overexpression of livin gene and downregulation of BMF gene in colon cancer cells. Further studies are warranted to understand the key regulators of the apoptotic mechanisms linked to this reciprocal regulation of BMF and livin gene in human colorectal cancer. A similar inverse relationship between BMF gene and survivin gene (another IAP family member) in human colorectal cancer has been described [15]. Our study speculate that, regulation of apoptotic mechanism in colon cancer tissues centered on reciprocal overexpression of anti-apoptotic livin and decreased expression of proapoptotic BMF gene.

In this study, we investigated livin and BMF gene expressions correlation with clinicopathological features in patients with cancer colon; more aggressive (stage IV), undifferentiated tumors, with metastasis were linked to increased livin gene and downregulation of BMF gene expressions, the reciprocal relation of both genes is connected to colon cancer aggressiveness.

In line with this study finding, regarding livin gene, Myung et al., stated that livin overexpression was significantly associated with advanced tumor stage, and lymph node metastasis in patients with cancer colon [13]. Also, Liu et al. reported a positive correlation between livin gene expression and metastasis in gastric cancer [18]. In this study, livin overexpression was presented with undifferentiated colon cancer, however this relation was insignificant, also, Xi et al. didn’t find any correlation between livin expression and the degrees of colon tumor differentiation [12].

In several tumor types upregulation of livin was predictive sign of more aggressive tumor [19], and was associated with tumor progression as it suppresses apoptosis and enhances metastasis by increasing tumor cell motility [20], those two results were reported and in agreement with our finding.

However, livin could not serve as a predictive sign in all kinds of cancers. Takeuchi et al. have demonstrated that livin expression in metastatic melanomas could not influence disease outcome and had no significant prognostic utility [21]. Kemphenstefen et al., also reported that high livin expression levels was present in well-differentiated renal cell and in early stage carcinomas and it did not correlate with pathological or clinical parameters and were not predictive of patient outcome [22].

Despite a lot of researches that suggested the role of livin as a predictive marker of tumor progression and patients prognosis in the majority of cancers. The tumor suppressive potential of BMF is just emerging [11].

In agreement with our finding, concerning downregulation of BMF expression in more aggressive (stage IV) undifferentiated colon tumor associated with metastasis, a recent study on human colon cancer cells reported that, lower expression of BMF gene promoted colon cancer cell...
There was a significant difference in BMF, p53 and livin gene expression level in regard to the tumor stage and presence of metastasis. #: Excluded from the comparison due to small number of cases (n = 1).

| Table 5 |
|-----------------------------------------------|
| Relation between BMF gene and livin gene expressions and Clinicopathologic data in group I (cancer colon cases) (n = 50). |
| Clinical tumor stage (TNM)                     |
|                                               |
| I 0                                            |
| II 7(14%)                                      |
| III 20(40%)                                    |
| IV 23(46%)                                     |
| Presence of metastasis                        |
| No 2.75(1.11 - 5.89)                           |
| Yes 0.95(0.45 - 2.80)                          |
| GEA mg/dl                                      |
| Normal 43(96%)                                 |
| Elevated 7(14%)                                |
| CA19-9 U/ml                                    |
| Normal 40(80%)                                 |
| Elevated 10(20%)                               |

| No(%)  | BMF gene expression  | p     | PS3 gene expression  | p     | Livin gene expression  | p     |
|--------|----------------------|-------|----------------------|-------|------------------------|-------|
|        | Median (min. – max.) |       | Median (min. – max.) |       | Median (min. – max.)   |       |
| I      | 0.044                |       | 8.12                 |       | 10(20%)                |       |
| II     | 2.99 (1.46 - 6.1)    |       | 11.89                |       | 40(80%)                |       |
| III    | 1.54 (0.45 - 6.1)    |       | 19.80                |       | 7(14%)                 |       |
| IV     | 0.98 (0.45 - 2.80)   |       | 19.42                |       | 23(46%)                |       |

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

There was a significant difference in BMF, p53 and livin gene expression level in regard to the tumor stage and presence of metastasis.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.

p values for Wilcoxon signed rank test

U, p: U and p values for Mann Whitney test *: Statistically significant at p ≤ 0.05.
to a sufficient extent to be named as authors. Dr Eman, Azza and Mohamed Assar do the lab investigation, Dr. Enas treat and follow up cancer colon patients at Clinical Oncology Department, and all authors participate in written and revision of the paper and approved the final manuscript for submission.

Declaration of competing interest

The authors declare that they have no conflict of interest.

Acknowledgement

We acknowledge the central laboratory unit, especially Eman Abd Elreheem Ghobashy, faculty of Medicine, Menoua University for providing us with the necessary instruments for completion of the study.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bbrep.2020.100747.

References

[1] Global Burden of Disease Cancer Collaboration, C. Fitzmaurice, C. Allen, Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study, JAMA Oncol. 3 (2017) 524.
[2] B. Ebeid, A. Abdelmohsen, A. Axon, Colorectal cancer in Egypt is commoner in young people: is this cause for alarm? Alexandria J. Med. (2014).
[3] M. Bettington, N. Walker, A. Clouston, The serrated pathway to colorectal carcinoma: current concepts and challenges, Histopathology 62 (2013) 367–386.
[4] L. Zhang, J. Yu, Role of apoptosis in colon cancer biology, therapy, and prevention, Curr. Colorectal. Cancer Rep. 9 (4) (2013), https://doi.org/10.1007/s11888-013-0188-z.
[5] Chong Xi, W. Shou Biao, G. Zhang Zhi, Significant elevation of survivin and livin expression in human colorectal cancer: inverse correlation between expression and overall survival, 34 (2011) 428–432.
[6] H. Zuo, The Effect of RNAi-Mediated Gene Silencing of Livin on the Growth and Apoptosis of SW480 Cells, (2012), p. R275-35.
[7] K.J. Campbell, S.W.G. Tait, Targeting BCL-2 regulated apoptosis in cancer, Open Biol. 8 (2018), https://doi.org/10.1098/rsob.180002.review.bcl2 180002.
[8] E. Eisenhauer, P. Therasse, J. Bogaerts, et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Canc. 45 (2009) 228–247.
[9] A.L. Phipps, P.J. Limburg, Baron, et al., Association between molecular subtypes of colorectal cancer and patient survival, Gastroenterology 148 (2015) 77–87 e2.
[10] Y. Wang, Y. Li, B. Zhou, et al., Expression of the apoptosis inhibitor livin in colorectal adenoma-carcinoma sequence: correlations with pathology and outcome, Tumour Biol. 35 (2014) 11791–11796.
[11] J.D. Piten, V. Lahi, A. Egle, et al., Bim and Bmf in tissue homeostasis and malignant diseases, Oncogene 27 (Suppl 1) (2008) 7–11.
[12] R.C. Xi, W.S. Biao, Z.Z. Gang, Significant elevation of survivin and livin expression in human colorectal cancer: inverse correlation between expression and overall survival, Onkologie 34 (8–9) (2011) 428–432.
[13] D.S. Myung, Y.L. Park, C.Y. Chung, et al., Expression of livin in colorectal cancer and its relationship to tumor cell behavior and prognosis, PLoS One 8 (9) (2013) e73622.
[14] B.S. Tan, K.H. Tsong, H.L. Choo, F.F. Chung, L.W. Hii, S.H. Tan, L.K. Yap, S. Pani, N.T. Khor, S.F. Wong, R. Kouis, S.K. Choong, C.O. Leong, Mutant p53 R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (Bmf), Cell Death Dis. 6 (2015) 191 Jul 16.
[15] R. Wang, Y. Kang, V. Christiane, et al., Reciprocal regulation of Bmf and BIRC5 (Survivin) linked to Eomes overexpression in colorectal cancer, Canc. Lett. 381 (2016) 341–348.
[16] X. Xie, Y. Huang, L. Chen, et al., miR-221 regulates proliferation and apoptosis of ovarian cancer cells by targeting BME, Oncol. Lett. 16 (2018) 6697–6704.
[17] Y. Kang, H. Nian, P. Rajendran, et al., HDAC8 and STAT3 repress BME gene activity in colon cancer cells, Cell Death Dis. 5 (2014) e1476.
[18] B. Liu, M. Han, J.K. Wen, et al., Livin/ML-IAP as a new target for cancer treatment, Canc. Lett. 250 (2) (2007) 168–176.
[19] D.K. Kim, C.S. Alvarado, C.R. Abramowsky, et al., Expression of inhibitor of apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome, Pediatr. Dev. Pathol. 8 (6) (2005) 621–629.
[20] Jaewon Choi, Y. Kyeong Hwang, Ki Woong Sung, et al., Expression of Livin, an antiapoptotic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia, Blood 109 (2) (2007) 471–477.
[21] H. Takeuchi, D.L. Morton, D. Elashoff, et al., Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine, Int. J. Canc. 117 (6) (2005) 1032–1038.
[22] C. Kempenkesten, S. Hinz, F. Christoph, et al., Expression of the apoptosis inhibitor livin in renal cell carcinomas: correlations with pathology and outcome [J], Tumour Biol. 28 (3) (2007) 132–135.
[23] M. Hornsveld, M. Tenhagen, R.A. van den Ven, et al., Restraining FOXO3-dependent transcriptional Bmf activation underpins tumour growth and metastasis of E-cadherin-negative breast cancer, Cell Death Differ. 23 (2016) 1483–1492.
[24] X.X. He, A.Y. Guo, C.R. Xu, et al., Bioinformatics analysis identifies miR-221 as a core regulator in hepatocellular carcinoma and its silencing suppresses tumor properties, Oncol. Rep. 32 (2014) 1200–1210.
[25] Z.Y. Ding, H. Zhang, G. Adell, et al., Livinexpression is an independent factor in rectal cancer patients with or without preoperative radiotherapy, Radiat. Oncol. 8 (2013) 281.
[26] J. Choi, Y.K. Hwang, K.W. Sung, et al., Expression of Livin, an antiprototopic protein, is an independent favorable prognostic factor in childhood acute lymphoblastic leukemia, Blood 109 (2007) 471–477.
[27] j Wang, G. Heb, Q. Yang, et al., B-cell lymphoma 2 is associated with advanced tumor grade and clinical stage, and reduced overall survival in young Chinese patients with colorectal carcinoma, Oncol. Lett. 15 (2018) 9009–9016.
[28] M. Melis, J. Hernandez, E.M. Siegel, M. Loughlin, Gene expression profiling of colorectal mucinous adenocarcinomas, Dis. Colon Rectum (6) (2010) 936–943, https://doi.org/10.1097/DCR.0b013e3181ed320c4.